Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating TAR-200 with cetrelimab or TAR-200 alone versus intravesical BCG in BCG-naïve high-risk non-muscle invasive bladder cancer (HR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Cetrelimab
• Intravesical Bacillus Calmette-Guérin (BCG)
• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING